NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
UMIN ID: UMIN000000802

Registered date:18/08/2007

Assessment of the Efficacy of Preoperative Exemestane Therapy for Endocrine-sensitive Postmenopausal Breast Cancer (SBCCSG-10)

Basic Information

Recruitment status Complete: follow-up complete
Health condition(s) or Problem(s) studiedPostmenopausal breast cancer
Date of first enrollment2007/08/01
Target sample size23
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)Exemestane (25 mg Tablet) is internally administered once a day everyday.

Outcome(s)

Primary OutcomeTime To Progression
Secondary Outcome1.Maximum efficacy period 2.Rate of tumor reduction 3.Relationship between pathological response rate and capacity of cell proliferation, activity of aromatase and functional analysis of estrogen receptor of breast cancer cells 4.Time To Treatment Failure 5.Adverse events 6.Changes in bone mineral density

Key inclusion & exclusion criteria

Age minimum60years-old
Age maximumNot applicable
GenderFemale
Include criteria
Exclude criteria1.Patients under chemotherapy and hormone therapy (for tumors) 2.Patients under treatment with the drugs (including HRT) that may influence on the conditions of sex hormone 3.Patients with a past history of breast cancer or with double cancer

Related Information

Contact

public contact
Name Toshihiro Kai
Address 3F, Capital Bldg. 4-261-1, Kishiki-cho, Omiya-ku, Saitama-City 330-0843, Saitama Prefecture Japan
Telephone 048-600-1722
E-mail toshikai@nyc.odn.ne.jp
Affiliation Saitama Breast Cancer Clinical Study Group (SBCCSG) Executive office(c/o: Shin-toshin Ladies' Clinic)
scientific contact
Name Toshio Tabei
Address 818 Komuro Ina Kitaadachi, Saitama 362-0806 Japan
Telephone 048-722-1111
E-mail
Affiliation Saitama Cancer Center Breast and Medical Oncology